Study to Investigate Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years and Over With Moderate to Severe Atopic Dermatitis With the Option of Rescue Treatment in Flaring Subjects

Last updated:
2026-07-11
Language and content disclaimer

The content and search results on this site are collected from or provided by third parties. As such some of the information may only be available in the language originally submitted by the sponsor of the trial. Learn more about the information on the search portal.

Linking to Non-Government of Canada Websites

Links to websites not under the control of the Government of Canada, including those to our social media accounts, and to clinical trial records in international registries are provided solely for the convenience of our website visitors. We are not responsible for the accuracy, currency or reliability of the content of such websites. The Government of Canada does not offer any guarantee in that regard and is not responsible for the information found through these links, nor does it endorse the sites and their content.

Visitors should also be aware that information offered by non-Government of Canada sites to which this website links is not subject to the Privacy Act or the Official Languages Act and may not be accessible to persons with disabilities. The information offered may be available only in the language(s) used by the sites in question. With respect to privacy, visitors should research the privacy policies of these non-government websites before providing personal information.

View trial details

Overview

Official protocol title:

A PHASE 3 RANDOMIZED WITHDRAWAL, DOUBLE BLIND, PLACEBO CONTROLLED, MULTI-CENTER STUDY INVESTIGATING THE EFFICACY AND SAFETY OF PF 04965842 IN SUBJECTS AGED 12 YEARS AND OVER, WITH MODERATE TO SEVERE ATOPIC DERMATITIS WITH THE OPTION OF RESCUE TREATMENT IN FLARING SUBJECTS

Intervention/treatment:
ABROCITINIB (PF-04965842)
Medical condition:
ATOPIC DERMATITIS
Protocol code:
B7451014
Control number:
217796
Status:
Closed
Approved:
July 23, 2018
Date Completed:
Trial phase:
Phase 3
For more information:
ClinicalTrials.gov - NCT03627767
This is an external link. The information is not authorized by the Government of Canada.

Eligibility

Sex: ALL
Age
12 Years and older
Accepts healthy volunteers: No

Contacts and locations

Contact
Name
Pfizer ClinicalTrials.gov Call Center
Organization
Pfizer Inc.
Phone:
1-800-718-1021
Sponsor
PFIZER CANADA INC

Locations

Alberta

Alberta Dermasurgery Center
Edmonton, Alberta, T6G1C3
Dermatology Research Institute
Calgary, Alberta, T1Y0B4
Stratica Medical
Edmonton, Alberta, T5K 1X3

Manitoba

Wiseman Dermatology Research Inc.
Winnipeg, Manitoba, R3M 3Z4

Newfoundland and Labrador

Karma Clinical Trials, Inc.
St. John's, Newfoundland and Labrador, A1A 4Y3

Ontario

AvantDerm
Toronto, Ontario, M5A 3R6
CCA Medical Research
Ajax, Ontario, L1S 7K8
Dermatology Ottawa Research Centre
Ottawa, Ontario, K2C 3N2
DermEdge Research
Mississauga, Ontario, L5H 1G9
K. Papp Clinical Research
Waterloo, Ontario, N2J 1C4
Lynderm Research Inc.
Markham, Ontario, L3P 1X2
Office of Dr. Paul Adam
Scarborough Village, Ontario, M1B 4Z8
SimcoDerm Medical and Surgical Dermatology Center
Barrie, Ontario, L4M 7G1
SKiN Centre for Dermatology
Peterborough, Ontario, K9J 5K2
XLR8 Medical Research Inc.
Windsor, Ontario, N8W 1E6

Quebec

Centre de Recherche Dermatologique du Quebec Metropolitain (CRDQ)
Québec, Quebec, G1V 4X7

Results

See the results from the trial NCT03627767. This is an external link. The information is not authorized by the Government of Canada.

Date posted:
Did you find what you were looking for?